Dabrafenib Tafinlar Capsule is an anti-cancer medicine that is used to treat certain types of cancer. It is typically used in combination with another medicine called trametinib. Both of these medicines slow the growth of cancer cells by inhibiting certain enzymes. DABRAFENIB TAFINLAR is typically used to treat advanced melanoma, although it may be used in other cancers as well.
The drug has a half-life of eight hours when administered orally, and approximately six hours for its metabolites hydroxy-dabrafenib and desmethyl-dabrafenib. Dabrafenib has a clearance rate of 17.0 L/h after a single dose and 44.4 L/h after repeated twice-daily dosing.
Dabrafenib is not known to be absorb into human milk. Because of this, it is not recommend to use this medication during pregnancy. Therefore, pregnant women should consult their doctor before starting this medication, especially if they are breastfeeding.
The drug may have side effects in some patients, including heart problems. These side effects may delay or even stop treatment. If you experience side effects, report them to the FDA. Moreover, dabrafenib may decrease the levels of other medicines in the blood, reducing their effectiveness or causing more side effects.
This drug is also known to increase the risk of certain type of cancer, such as skin cancer. The dosage of dabrafenib depends on the type of cancer you have. If you have a tumor that contains BRAF mutation, dabrafenib is an effective treatment. It works by blocking the proteins made by the changed BRAF gene, which slows down the growth of cancer cells. It is take in capsule form and is usually take with a full glass of water.
In addition to its ability to slow tumor growth, DABRAFENIB TAFINLR is also an effective treatment for metastatic disease. It targets the V600E mutated BRAF protein, which inhibits the proliferation of cancer cells. Dabrafenib is administer to patients by mouth, in the form of 50 mg or 75 mg capsules. Patients are typically treated with dabrafenib until their disease worsens, or they experience unacceptable side effects.
Clinical trials for DABRAFENIB TAFINLAR have demonstrated promising results. One such study included 26 patients with ATC. Although the study did not include sufficient numbers of younger patients, it was able to identify the potential side effects of Dabrafenib Tafinlar Capsule
If you are on hormonal birth control, dabrafenib may reduce the effectiveness of your treatment. The drug may also cause a skin rash, which may require hospitalization. Additionally, if you are breastfeeding, you should inform your doctor immediately. It is also important to discuss your pregnancy plans with your doctor if you are taking DABRAFENIB TAFINLAR Capsule.
Dabrafenib Tafinlar Capsule can impair glucose control in diabetic patients, so patients should be monitor closely. It may also cause hemolytic anemia in patients with G6PD deficiency. Patients with G6PD deficiency should notify their healthcare provider immediately if they experience symptoms of hemolytic anemia